Screening for Mild Cognitive Impairment (MCI) in patients with subjective memory complaints.
Evaluating cognitive domains in early-stage dementia where the MMSE may show a ceiling effect.
Monitoring cognitive status in neurodegenerative conditions (e.g., Parkinson’s, Alzheimer’s).
Post-stroke cognitive screening.
Section 2
Formula & Logic
Scoring Component
The MoCA is a 30-point test. It assesses multiple cognitive domains including executive functions, naming, memory, attention, language, abstraction, delayed recall, and orientation.
Scoring Thresholds
Score ≥ 26
Normal cognitive function
Score < 26
Suggestive of Mild Cognitive Impairment (MCI)
Education Adjustment
Add 1 point if patient has ≤ 12 years of formal education (and total < 30)
Section 3
Pearls/Pitfalls
MoCA vs. MMSE
The MoCA is significantly more sensitive than the MMSE for detecting MCI. While the MMSE focuses on orientation and memory, the MoCA includes robust executive function and abstraction tasks.
Clinical Pearls
The "Clock Drawing Test" item is a powerful screen for executive and visuospatial dysfunction.
Delayed recall is the most sensitive item for early Alzheimer’s pathology.
Do not interpret a score of 25 as "safe"; patients with high premorbid intelligence may score in the "normal" range despite significant functional decline.
Section 4
Next Steps
Diagnostic Pathway
01
Score < 26: Conduct a detailed clinical history focusing on Activities of Daily Living (ADLs) and Instrumental ADLs.
02
Workup: Consider blood work (TSH, B12, RPR) and neuroimaging (MRI Brain) to rule out reversible causes of cognitive decline.
03
Specialist Referral: Formal neuropsychological testing is indicated if the MoCA score is borderline or if there is a discrepancy between test performance and clinical presentation.
Section 5
Evidence Appraisal
Primary Reference
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine ZS et al. • Journal of the American Geriatrics Society. 2005;Vol 53, Issue 4. pp. 695-699. The definitive validation paper.
Section 6
Literature
Ziad Nasreddine
Developed by Dr. Ziad Nasreddine in Montreal, Canada. It has since been translated into over 35 languages and is a global standard in geriatric medicine.
